- Introduction and Context: NAFLD, Obesity, and Diabetes
- Weight loss in NAFLD
- Antidiabetic medications in NAFLD
- GLP-1 agonists
- SGLT2 inhibitors
- Investigational agents
Access Webcast Here: https://event.webcasts.com/starthere.jsp?ei=1231407&tp_key=220b8c16c4
Click on the link above to attend the presentation from your laptop, tablet or mobile device. Audio will stream through your selected device, so be sure to have headphones or your volume turned up. The platform works best with the Chrome browser, but will work with other internet browsers.
Raymond Soccio, MD
Assistant Professor of Medicine
Division of Endocrinology, Diabetes, and Metabolism
University of Pennsylvania Health System
Crescenz Philadelphia VA Medical Center
The goal of this activity is to improve participants’ competence in identifying and managing patients with or at risk for NASH, and in knowledge of emerging NASH therapies.
This program is intended for endocrinologists, gastroenterologists, hepatologists nurses, and other healthcare providers who care for patients with or at risk for NASH.
Upon completion of this activity, participants should be able to:
- Evaluate risk and apply appropriate methodology to characterize NAFLD and diagnose NASH in individual patients
- Apply best practices in the management of patients with NAFLD based on evolving data on lifestyle modification and medical treatment
- Critically evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH
- Demonstrate an understanding of clinical trial design and evaluation of endpoints in the setting of NAFLD/NASH
Physician Continuing Medical Education
American Gastroenterological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
American Gastroenterological Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Disclosure of Conflicts of Interest
The American Gastroenterological Association requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the AGA policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.